Nemes Rush Group LLC Bio Line Rx Ltd. Transaction History
Nemes Rush Group LLC
- $728 Billion
- Q2 2024
A detailed history of Nemes Rush Group LLC transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Nemes Rush Group LLC holds 12,000 shares of BLRX stock, worth $7,560. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,000
Previous 12,000
-0.0%
Holding current value
$7,560
Previous $13.4 Million
49.11%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BLRX
# of Institutions
37Shares Held
4.29MCall Options Held
49.9KPut Options Held
122K-
Alyeska Investment Group, L.P. Chicago, IL1.95MShares$1.23 Million0.01% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$513,8804.05% of portfolio
-
Envestnet Asset Management Inc214KShares$134,7140.0% of portfolio
-
Values First Advisors, Inc.204KShares$128,3680.07% of portfolio
-
Pvg Asset Management Corp Golden, CO124KShares$77,8550.3% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $38.8M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...